Welcome & Introduction

Lorlatinib as front-line option in ALK+ mNSCLC

Per-operative Therapy-Neoadjuvant and Adjuvant Immunotherapy

Role of Dual I-O Therapy in treatment of 1L mNSCLC

Case Based Panel Discussion | Optimal management of 1L ES-SCLC

Panel Discussion | Is using the best drug first ideal strategy in the treatment of metastatic NSCLC

Panel Discussion | Optimal Sequencing of ALK-TKIS

Closing Remarks